June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Ophthalmology/Optometry Allergic Rhinoconjunctivitis Patient Treatment; The Allergies, Immunotherapy & RhinoconjunctivitiS (AIRS) Provider Survey
Author Affiliations & Notes
  • Leonard Bielory
    Rutgers University, New Brunswick, NJ
    Robert Wood Johnson University Hospital, New Brunswick, NJ
  • Mark Dykewicz
    Wake Forrest Baptist Health, Winston-Salem, NC
  • Timothy Craig
    Division of Pulmonary, Allergy and Critical Care, Penn State University, Winston-Salem, PA
  • Michael Blaiss
    Allergy & Asthma Care, Germantown, TN
  • Bryan Leatherman
    Coastal ENT Associates, Gulfport, MS
  • David Skoner
    Pediatrics, West Penn Allegheny Health System, Cranberry Township, PA
  • Nancy Smith
    Global Health Outcomes, Merck & Co., Inc, Whitehouse Station, NJ
  • F. Allen-Ramey
    Global Health Outcomes, Merck & Co., Inc, West Point, PA
  • Footnotes
    Commercial Relationships Leonard Bielory, Merck (C), Allergan (C), Bausch & Lomb (C); Mark Dykewicz, Merck (C); Timothy Craig, Merck (C); Michael Blaiss, Merck (C), GSK (R), AstraZeneca (R), Meda (R), Sunovion (R), Takeda (R), Genentech (R), Teva (R), Proctor and Gamble (C), Nestle's (R), Pfizer (C), PMD Healthcare (C), Sanofi (C); Bryan Leatherman, Merck (C), Sunovion (C), Teva (C), Alk Abello (C); David Skoner, Greer Laboratories (F), Novartis (R), Merck (R), GlaxoSmithKline (R), Teva (R), Sunovion (R), Istavvision (C); Nancy Smith, None; F. Allen-Ramey, Merck & Co., Inc. (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 888. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Leonard Bielory, Mark Dykewicz, Timothy Craig, Michael Blaiss, Bryan Leatherman, David Skoner, Nancy Smith, F. Allen-Ramey; Ophthalmology/Optometry Allergic Rhinoconjunctivitis Patient Treatment; The Allergies, Immunotherapy & RhinoconjunctivitiS (AIRS) Provider Survey. Invest. Ophthalmol. Vis. Sci. 2013;54(15):888. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: Allergic Rhinoconjunctivitis (ARC) is one of the most common chronic diseases in the US and specific immunotherapy (SIT) is one of the most effective therapies. The AIRS survey was designed to assess providers' perceptions of patient symptomatology, allergy testing and treatment.

Methods: A telephone survey was administered to 500 healthcare providers offering outpatient care to >1 ARC patient per week. Providers were randomly selected from professional society lists stratified by specialty to yield completed surveys from 100 Allergy/Immunology, 100 Otolaryngologists (ENTs), 75 Family Medicine, 75 Pediatrics and 50 Ophthalmology/Optometry providers along with 50 Nurse Practitioners (NP) and 50 Physician Assistants (PA).

Results: Ophthalmology/Optometry (OPH/OPT) providers reported managing an average of 15 adult (≥18 years) and 6 pediatric (<18 years) ARC patients/ week; with the most common complaint reported being ocular symptoms. Sixty-two per cent watery or teary eyes,and 24% red eyes. Nasal symptoms were reported less frequently by all providers with 58% reporting nasal congestion, 35% runny nose, 27% repeated sneezing, 16% post-nasal drip, 12% nasal itching and 14% cough. All provider groups reported ocular symptoms more frequently than nasal symptoms, with the exception of ENT providers. In addition, OPH/OPT reported the most infrequent use of allergy diagnostic testing such as skin or blood tests at 4% of patients. OPH/ OPT reported similar severity of patients to that of other provider groups with 96% reporting at least a moderate amount of impact on their patients' quality of life (QOL). However, a sizeable proportion of OPH/OPT (14%) do not refer or provide specific immunotherapy (SIT), as compared to other provider groups (< 5%), although 70% of OPH/OPT believed that SIT was more efficacious than symptomatic medications.

Conclusions: Eye care specialists commonly see patients with ARC and appreciate the benefits of immunotherapy. As compared to some other provider groups, eye care specialists perform allergy testing infrequently and are less likely to recommend SIT or refer unresponsive patients to another healthcare provider. Education of ophthalmologists/optometrists on effectiveness of immunotherapy may improve patient outcomes since SIT alleviates all symptoms of ARC including ocular symptoms.

Keywords: 475 conjunctivitis • 460 clinical (human) or epidemiologic studies: health care delivery/economics/manpower  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.